LRRC50 Antibody (OTI2C4) [DyLight 755]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-72536IR
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human, Mouse, Rat, Canine, Monkey, Primate
Applications
Flow Cytometry, Western Blot
Label
DyLight 755 (Excitation = 754 nm, Emission = 776 nm)
Antibody Source
Monoclonal Mouse IgG1 Clone # OTI2C4
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Full length recombinant protein of human LRRC50 (NP_848547) produced in HEK293T cells.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for LRRC50 Antibody (OTI2C4) [DyLight 755]
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: LRRC50
Alternate Names
CILD13, DKFZp434A119, FLJ25330, leucine rich repeat containing 50, ODA7leucine-rich repeat-containing protein 50, outer row dynein assembly 7 homolog
Gene Symbol
DNAAF1
Additional LRRC50 Products
Product Documents for LRRC50 Antibody (OTI2C4) [DyLight 755]
Product Specific Notices for LRRC50 Antibody (OTI2C4) [DyLight 755]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...